Full-Time
Senior Factory Service Engineer
Factory Service Engineering
Posted on 10/31/2025
Synthego
51-200 employees
Supplies synthetic RNA and gene-editing tools.
Compensation Overview
$100k - $120k/yr
San Carlos, CA, USA
In Person
 Mechanical Engineering (3) |
|---|
| , , |
- BS degree in Mechanical Engineering, Electrical Engineering, Industrial Engineering or related field
- 5+ years of industry experience working with industrial and instrument controls and/or oligonucleotide synthesis equipment
- Familiarity with CAPAs and nonconformance reports, performing Root Cause Analysis (RCA)
- Experience debugging complex systems, communicating failure modes, and bringing systems back online
- Understand and apply GMP and GDP principles in manufacturing
- Effective and proactive written and verbal communication skills
- Comfortable working around and with hazardous materials and waste used in a chemical lab setting
- An eagerness to understand and fix and improve mechanical life sciences equipment
- You will serve as the point of contact for supporting our lab automation and manufacturing equipment.
- Respond to unplanned equipment breakdowns, identify root causes, replace parts, bolster the spare parts inventory, and identify ways to improve equipment reliability.
- Provide detailed symptom descriptions for failures uncovered during functional tests and calibration to assist in component-level troubleshooting.
- Schedule and perform routine maintenance and calibration, working with both internal stakeholders in planning and external vendors to ensure no disruptions to the manufacturing schedule.
- Provide the highest quality of service and support to our manufacturing shop floor.
- Create, maintain, and review standard operating procedures (SOPs) as well as conduct training events.
- Continuously optimize processes to improve safety, quality, and reliability.
- Maintain spare parts inventory, tools, certified test equipment, and items related to the Factory Service Engineering team.
- Experience with GE/Cytiva (oligoprocess, Pilot 600s and OligoPilots) synthesis equipment, Agilent & Waters HPLC, LCMS, QTOF, GC systems, Hamilton Liquid Handlers.
- Ability to work with and configure computer hardware and software.
- Ability to read mechanical drawings and wiring schematics.
- Previous experience in the Biotech / life sciences domain.
- Familiarity with Python is a plus.
- Experience with controls, PLCs (Beckhoff or Studio5000), HMIs, and SCADA (Ignition or FactoryTalk) systems
Synthego provides tools and services for genetic engineering. It sells synthetic RNA and gene editing reagents that researchers use to modify genes, and it offers a platform that gives users access to advanced gene editing workflows. The products are used by research institutions, pharmaceutical companies, and biotech startups for drug discovery, disease modeling, and genetic research. Unlike competitors that only offer individual components, Synthego combines both physical gene-editing tools and an integrated platform to support end-to-end genetic engineering work. The company’s goal is to help researchers perform gene editing more efficiently and at scale, accelerating discoveries in medicine and agriculture.
Company Size
51-200
Company Stage
Series E
Total Funding
$459.7M
Headquarters
Menlo Park, California
Founded
2012
Simplify's Take
What believers are saying
- Perceptive Advisors acquired Synthego on July 18, 2025, bolstering financial stability.
- Strategic deals with AstraZeneca and HuidaGene expand nuclease portfolio for therapies.
- Dr. Bill Skarnes joined advisory board, enhancing stem cell genome engineering expertise.
What critics are saying
- Perceptive demands cut R&D spending within 6-12 months, eroding innovation edge.
- EditCo Bio spinout diverts talent and clients from core CRISPR business immediately.
- IP disputes in AstraZeneca and HuidaGene licenses halt GMP lines in 12-18 months.
What makes Synthego unique
- Synthego vertically integrates hardware, software, and GMP CRISPR for precise genome engineering.
- Synthego licenses advanced nucleases like hfCas12Max and eSpOT-ON from AstraZeneca and Vita.
- Synthego delivers AccuBase base editors via Base Therapeutics and KACTUS partnerships.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Synthego who can refer or advise you
Benefits
Generous Equity Package
Medical, Dental & Vision
401(k) Plan
Catered to You
Fully Stocked
Transportation
Green Environment
Stay Fit
Legal Ease
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -2%Base Therapeutics and KACTUS announce strategic partnership with Synthego to advance GMP AccuBase(TM) base editing platform. Home / news & articles / Base Therapeutics and KACTUS announce strategic partnership with Synthego to advance GMP AccuBase(TM) base editing platform. Base Therapeutics and KACTUS are excited to announce a strategic partnership with Synthego for the distribution of the AccuBase(TM) cytosine base editor. This collaboration aims to accelerate innovation and accessibility of next-generation cell and gene therapies. This agreement integrates Base Therapeutics' pioneering base-editing technologies, and KACTUS' leadership in enzyme design and GMP-grade production with Synthego's industry-leading RUO-to-GMP CRISPR Solutions to address unmet needs in the rapidly evolving field of genomic medicine. "We are thrilled to collaborate with Synthego and Base Therapeutics to meet the needs of our global customers and accelerate the availability of therapeutic solutions for disease treatment. Through this alliance, we aim to advance the research and industrialization of cell and gene therapy," said Edmund Wang, CEO of KACTUS. Traditional CRISPR editing systems such as Cas9 or Cas12 rely on DNA double-strand breaks, introducing risks such as chromosomal loss or translocation. In contrast, the AccuBase(TM) cytosine base editor represents "CRISPR 2.0" technology that enables ultra-precise, cell-friendly editing with near-zero off-target effects. As the only GMP-grade base editing proteins currently available, AccuBase(TM) marks a new era for gene editing, shifting from "cutting" to "precision modification". "AccuBase(TM) is the next evolution of our clinical-grade solutions, complementing our best-in-class Guide RNA with a powerful base editing platform. With over five years of proven GMP experience and regulatory guidance, we are uniquely positioned to empower our therapeutic partners and accelerate their path to the clinic," said Craig Christianson, CEO of Synthego. "This partnership represents an important milestone in the global expansion of AccuBase(TM). We look forward to working with therapeutic partners to ensure that gene-editing technologies truly benefit human health worldwide," said Dr. Tianhong Xu, Founder and CEO of Base Therapeutics. As a leading supplier in cell and gene therapy, KACTUS provides an extensive portfolio of gene-editing enzymes - including GMP-grade Cas9 (FDA DMF filed) and GMP-grade AccuBase(TM)- to support customers throughout the IND and clinical phases of drug development. By integrating their respective scientific, commercial and regulatory strengths, this strategic partnership will advance the development of next-generation gene editing technologies, establishing a new standard for safe and effective tools in therapeutic applications. About KACTUS. KACTUS is an innovation-driven company specializing in recombinant proteins and enzyme materials to support the development and manufacturing of biopharmaceuticals. Established in 2018, KACTUS has built deep expertise in protein R&D and production through its proprietary structure-designed protein platform, SAMS(TM). With its own 100,000 square foot GMP facility and certified quality system, KACTUS supplies a broad range of GMP-grade raw proteins and enzymes tailored to the needs of cell and gene therapy drug development. About Synthego. Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health. By providing unparalleled access to CRISPR solutions at scale, Synthego enables agility in life science discovery and clinical advancement. With streamlined licensing models and exceptional technical expertise, Synthego empowers researchers and developers to unlock better patient outcomes through innovative CRISPR cell and gene therapies. Recognized in hundreds of peer-reviewed publications and trusted by thousands of researchers and therapeutic developers, Synthego is driving the future of medicine through cutting-edge genome-editing technologies. About Base Therapeutics. Founded in 2021, Base Therapeutics is a high-tech enterprise focused on breakthrough innovations in gene editing. The company holds more than 30 domestic and international patents and is developing first-in-class cell and gene-editing products, particularly in cancer and rare genetic diseases. Its pipeline includes base-editing CAR-T and in vivo base-editing therapies, as well as NK510 and NK520 programs. Base Therapeutics' NK cell base-editing therapies are already in clinical studies exploring efficacy and safety in relapsed, refractory, and metastatic solid and hematologic tumors where conventional chemotherapy has failed.
Synthego has completed the sale of nearly all its assets to funds managed by Perceptive Advisors, finalized on July 18, 2025. Under Perceptive's ownership, Synthego will continue its operations with the same leadership and brand. The acquisition aims to enhance Synthego's financial position and accelerate innovation in CRISPR solutions. Recent product expansions include a GMP version of SpCas9 and new enzymes, eSpOT-ON and Accubase.
Perceptive Advisors' acquisition of Synthego, a leader in CRISPR solutions, has been cleared to close in July.
Synthego introduced the hfCas12Max CRISPR system in 2024, the first in its portfolio of high-fidelity nucleases designed specifically for therapeutic applications.
REDWOOD CITY, Calif., April 8, 2025 /PRNewswire/ -- Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into Vita's cell therapeutic programs. This nonexclusive sublicense grants Vita Therapeutics access to the engineered hfCas12Max nuclease and optimized hfCas12Max guide RNAs for use in preclinical and clinical applications, including in potential commercialized therapeutics. "With the integration of hfCas12Max, Vita Therapeutics can accelerate the development of their hypoimmunogenic cell therapies, paving the way for life-changing treatments to reach patients sooner," said Craig Christianson, CEO of Synthego. "Our goal is to make therapeutic CRISPR solutions more accessible by removing traditional bottlenecks with reduced upfront licensing fees and a lower total IP cost as the therapy advances."